0.8916

1.32% 0.0116

Chimerix Inc (CMRX)

Overview News Price History Option Chain Financials Discussions Forecast

Chimerix Inc stock is traded at $0.8916, with a volume of 13,585. It is up +1.32% in the last 24 hours and up +1.32% over the past month. Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Previous Close:

$0.88

Open:

$0.87

24h Volume:

13,585

Relative Volume:

0.05

Market Cap:

$80.11M

Revenue:

$324.00K

Net Income/Loss:

$-82.10M

P/E Ratio:

0.4328

EPS:

2.06

Net Cash Flow:

$-69.18M

1W Performance:

-0.79%

1M Performance:

+1.32%

6M Performance:

-8.55%

1Y Performance:

-7.13%

1-Day Range:

$0.87

$0.9035

1-Week Range:

$0.8301

$0.92

52-Week Range:

$0.75

$1.30

Chimerix Inc Stock (CMRX) Company Profile

Name

Chimerix Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

919.806.1074

Address

2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC

Employee

Twitter

@chimerix

Next Earnings Date

2024-11-07

Latest SEC Filings

CMRX's Discussions on Twitter

Compare CMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMRX	0.903	80.11M	324.00K	-82.10M	-69.18M	2.06
VRTX	447.96	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	742.12	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.39	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.31	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.70	24.49B	3.30B	-501.07M	1.03B	11.54

Chimerix Inc Stock (CMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-07-22	Initiated	CapitalOne	Overweight
Apr-29-21	Initiated	Maxim Group	Buy
Apr-23-21	Resumed	Cowen	Outperform
Mar-31-21	Initiated	Jefferies	Buy
Mar-31-21	Initiated	Wedbush	Outperform
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Feb-02-18	Initiated	H.C. Wainwright	Buy
Aug-09-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Barclays	Overweight → Equal Weight
Feb-23-16	Reiterated	FBR Capital	Mkt Perform
Feb-23-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Feb-22-16	Downgrade	Citigroup	Buy → Neutral
Dec-29-15	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-15	Downgrade	FBR Capital	Outperform → Mkt Perform
Dec-28-15	Reiterated	Piper Jaffray	Overweight
Dec-17-15	Initiated	UBS	Buy
Oct-05-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-03-15	Initiated	Citigroup	Buy
Aug-18-15	Initiated	FBR Capital	Outperform
Aug-06-15	Reiterated	Brean Capital	Buy
May-11-15	Reiterated	Brean Capital	Buy
Mar-04-15	Initiated	Barclays	Overweight
Feb-12-15	Reiterated	Stifel	Buy
Dec-31-14	Reiterated	Brean Capital	Buy
Jul-08-14	Resumed	Brean Capital	Buy

View All

Chimerix Inc Stock (CMRX) Latest News

Nov 20, 2024

Chimerix (FRA:CXF) Change In Receivables : €-0.13 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 20, 2024

Chimerix (CMRX) Announces Updated Phase 2 Response Assessment of Dordaviprone - StreetInsider.com

Nov 11, 2024

Chimerix Cancer Drug Shows 28% Response Rate in Phase 2 Brain Tumor Trial | CMRX Stock News - StockTitan

Nov 11, 2024

Nov 09, 2024

Wedbush Reaffirms “Outperform” Rating for Chimerix (NASDAQ:CMRX) - Defense World

Nov 09, 2024

Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Chimerix Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 08, 2024

Earnings call: Chimerix reports progress and financials for Q3 2024 - Investing.com India

Nov 08, 2024